BACKGROUND: H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven medical therapies. The entity predominantly occurs in children and young adults. ONC201 is a small molecule selective antagonist of dopamine receptor D2/3 (DRD2/3) with an exceptional safety profile. Following up on a durable response in the first H3 K27M-mutant diffuse midline glioma patient who received ONC201 (NCT02525692), an expanded access program was initiated. METHODS: Patients with H3 K27M-mutant gliomas who received at least prior radiation were eligible. Patients with leptomeningeal spread were excluded. All patients received open-label ONC201 orally once every week. Safety, radiographic assessments, and overall survival were regularly assessed at least every 8 weeks by investigators. As of August 2018, a total of 18 patients with H3 K27M-mutant diffuse midline glioma or DIPG were enrolled to single patient expanded access ONC201 protocols. Among the 18 patients: seven adult (> 20 years old) and seven pediatric (< 20 years old) patients initiated ONC201 with recurrent disease and four pediatric patients initiated ONC201 following radiation, but prior to disease recurrence. FINDINGS: Among the 14 patients with recurrent disease prior to initiation of ONC201, median progression-free survival is 14 weeks and median overall survival is 17 weeks. Three adults among the 14 recurrent patients remain on treatment progression-free with a median follow up of 49.6 (range 41-76.1) weeks. Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progression-free for at least 53 and 81 weeks. Radiographic regressions, including a complete response, were reported by investigators in a subset of patients with thalamic and pontine gliomas, along with improvements in disease-associated neurological symptoms. INTERPRETATION: The clinical outcomes and radiographic responses in these patients provide the preliminary, and initial clinical proof-of-concept for targeting H3 K27M-mutant diffuse midline glioma with ONC201, regardless of age or location, providing rationale for robust clinical testing of the agent.
BACKGROUND: H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven medical therapies. The entity predominantly occurs in children and young adults. ONC201 is a small molecule selective antagonist of dopamine receptor D2/3 (DRD2/3) with an exceptional safety profile. Following up on a durable response in the first H3 K27M-mutant diffuse midline gliomapatient who received ONC201 (NCT02525692), an expanded access program was initiated. METHODS:Patients with H3 K27M-mutant gliomas who received at least prior radiation were eligible. Patients with leptomeningeal spread were excluded. All patients received open-label ONC201 orally once every week. Safety, radiographic assessments, and overall survival were regularly assessed at least every 8 weeks by investigators. As of August 2018, a total of 18 patients with H3 K27M-mutant diffuse midline glioma or DIPG were enrolled to single patient expanded access ONC201 protocols. Among the 18 patients: seven adult (> 20 years old) and seven pediatric (< 20 years old) patients initiated ONC201 with recurrent disease and four pediatric patients initiated ONC201 following radiation, but prior to disease recurrence. FINDINGS: Among the 14 patients with recurrent disease prior to initiation of ONC201, median progression-free survival is 14 weeks and median overall survival is 17 weeks. Three adults among the 14 recurrent patients remain on treatment progression-free with a median follow up of 49.6 (range 41-76.1) weeks. Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPGpatients remain progression-free for at least 53 and 81 weeks. Radiographic regressions, including a complete response, were reported by investigators in a subset of patients with thalamic and pontine gliomas, along with improvements in disease-associated neurological symptoms. INTERPRETATION: The clinical outcomes and radiographic responses in these patients provide the preliminary, and initial clinical proof-of-concept for targeting H3 K27M-mutant diffuse midline glioma with ONC201, regardless of age or location, providing rationale for robust clinical testing of the agent.
Authors: Mark N Stein; Joseph R Bertino; Howard L Kaufman; Tina Mayer; Rebecca Moss; Ann Silk; Nancy Chan; Jyoti Malhotra; Lorna Rodriguez; Joseph Aisner; Robert D Aiken; Bruce G Haffty; Robert S DiPaola; Tracie Saunders; Andrew Zloza; Sherri Damare; Yasmeen Beckett; Bangning Yu; Saltanat Najmi; Christian Gabel; Siobhan Dickerson; Ling Zheng; Wafik S El-Deiry; Joshua E Allen; Martin Stogniew; Wolfgang Oster; Janice M Mehnert Journal: Clin Cancer Res Date: 2017-03-22 Impact factor: 12.531
Authors: Chiaki T Ishida; Yiru Zhang; Elena Bianchetti; Chang Shu; Trang T T Nguyen; Giulio Kleiner; Maria J Sanchez-Quintero; Catarina M Quinzii; Mike-Andrew Westhoff; Georg Karpel-Massler; Varun V Prabhu; Joshua E Allen; Markus D Siegelin Journal: Clin Cancer Res Date: 2018-07-23 Impact factor: 12.531
Authors: Peter W Lewis; Manuel M Müller; Matthew S Koletsky; Francisco Cordero; Shu Lin; Laura A Banaszynski; Benjamin A Garcia; Tom W Muir; Oren J Becher; C David Allis Journal: Science Date: 2013-03-28 Impact factor: 47.728
Authors: C Leah B Kline; A Pieter J Van den Heuvel; Joshua E Allen; Varun V Prabhu; David T Dicker; Wafik S El-Deiry Journal: Sci Signal Date: 2016-02-16 Impact factor: 8.192
Authors: Jo Ishizawa; Kensuke Kojima; Dhruv Chachad; Peter Ruvolo; Vivian Ruvolo; Rodrigo O Jacamo; Gautam Borthakur; Hong Mu; Zhihong Zeng; Yoko Tabe; Joshua E Allen; Zhiqiang Wang; Wencai Ma; Hans C Lee; Robert Orlowski; Dos D Sarbassov; Philip L Lorenzi; Xuelin Huang; Sattva S Neelapu; Timothy McDonnell; Roberto N Miranda; Michael Wang; Hagop Kantarjian; Marina Konopleva; R Eric Davis; Michael Andreeff Journal: Sci Signal Date: 2016-02-16 Impact factor: 8.192
Authors: Jie Li; Shan Zhu; David Kozono; Kimberly Ng; Diahnn Futalan; Ying Shen; Johnny C Akers; Tyler Steed; Deepa Kushwaha; Michael Schlabach; Bob S Carter; Chang-Hyuk Kwon; Frank Furnari; Webster Cavenee; Stephen Elledge; Clark C Chen Journal: Oncotarget Date: 2014-02-28
Authors: Pawel Buczkowicz; Christine Hoeman; Patricia Rakopoulos; Sanja Pajovic; Louis Letourneau; Misko Dzamba; Andrew Morrison; Peter Lewis; Eric Bouffet; Ute Bartels; Jennifer Zuccaro; Sameer Agnihotri; Scott Ryall; Mark Barszczyk; Yevgen Chornenkyy; Mathieu Bourgey; Guillaume Bourque; Alexandre Montpetit; Francisco Cordero; Pedro Castelo-Branco; Joshua Mangerel; Uri Tabori; King Ching Ho; Annie Huang; Kathryn R Taylor; Alan Mackay; Anne E Bendel; Javad Nazarian; Jason R Fangusaro; Matthias A Karajannis; David Zagzag; Nicholas K Foreman; Andrew Donson; Julia V Hegert; Amy Smith; Jennifer Chan; Lucy Lafay-Cousin; Sandra Dunn; Juliette Hukin; Chris Dunham; Katrin Scheinemann; Jean Michaud; Shayna Zelcer; David Ramsay; Jason Cain; Cameron Brennan; Mark M Souweidane; Chris Jones; C David Allis; Michael Brudno; Oren Becher; Cynthia Hawkins Journal: Nat Genet Date: 2014-04-06 Impact factor: 38.330
Authors: Gang Wu; Alexander K Diaz; Barbara S Paugh; Sherri L Rankin; Bensheng Ju; Yongjin Li; Xiaoyan Zhu; Chunxu Qu; Xiang Chen; Junyuan Zhang; John Easton; Michael Edmonson; Xiaotu Ma; Charles Lu; Panduka Nagahawatte; Erin Hedlund; Michael Rusch; Stanley Pounds; Tong Lin; Arzu Onar-Thomas; Robert Huether; Richard Kriwacki; Matthew Parker; Pankaj Gupta; Jared Becksfort; Lei Wei; Heather L Mulder; Kristy Boggs; Bhavin Vadodaria; Donald Yergeau; Jake C Russell; Kerri Ochoa; Robert S Fulton; Lucinda L Fulton; Chris Jones; Frederick A Boop; Alberto Broniscer; Cynthia Wetmore; Amar Gajjar; Li Ding; Elaine R Mardis; Richard K Wilson; Michael R Taylor; James R Downing; David W Ellison; Jinghui Zhang; Suzanne J Baker Journal: Nat Genet Date: 2014-04-06 Impact factor: 38.330
Authors: Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: James L Ross; Zhihong Chen; Cameron J Herting; Yura Grabovska; Frank Szulzewsky; Montserrat Puigdelloses; Lenore Monterroza; Jeffrey Switchenko; Nitin R Wadhwani; Patrick J Cimino; Alan Mackay; Chris Jones; Renee D Read; Tobey J MacDonald; Matthew Schniederjan; Oren J Becher; Dolores Hambardzumyan Journal: Brain Date: 2021-02-12 Impact factor: 13.501
Authors: Erin R Bonner; Sebastian M Waszak; Michael A Grotzer; Sabine Mueller; Javad Nazarian Journal: Neuro Oncol Date: 2021-04-12 Impact factor: 12.300
Authors: Amy K Bruzek; Karthik Ravi; Ashwath Muruganand; Jack Wadden; Clarissa May Babila; Evan Cantor; Leo Tunkle; Kyle Wierzbicki; Stefanie Stallard; Robert P Dickson; Ian Wolfe; Rajen Mody; Jonathan Schwartz; Andrea Franson; Patricia L Robertson; Karin M Muraszko; Cormac O Maher; Hugh J L Garton; Tingtin Qin; Carl Koschmann Journal: Clin Cancer Res Date: 2020-10-21 Impact factor: 12.531